Serina Therapeutics vs Soligenix
SER and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SER and SNGX compare
Serina Therapeutics is the larger company, worth 5.2 times as much as Soligenix ($36.3M against $7.0M).
Soligenix scores higher on the StockData Score (6 against 2 for Serina Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SER | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $36.3M | $7.0M |
| Share price | $1.43 | $0.321 |
| Change, 1 year | −63.4% | −76.4% |
| Change, 5 years | 81.0% | −99.8% |
| Beta (5Y) | −1.09 | 0.62 |
| Employees | 16 | 14 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.1× |
| FCF yield | −58.4% | – |
| Growth | ||
| Revenue growth, 5Y average | −18.5% | – |
| Profitability | ||
| Return on equity | −1175% | −127% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 6.65 (better) | 3.00 |
| Altman Z-score | −0.10 (better) | −38.47 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 5.5% | 4.3% |
| Held by insiders | 49.7% | 0.69% |
| Insider net buying, 12 months | −$232K | – |
| Short interest, % of float | 0.37% | 0.31% |
Go deeper
- SER stock overview
- SER income statement
- SER valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.